Allan Zijian Zhao PhD

Chairman

Allan Zijian Zhao, PhD, founder and chairman of Sinogen, National Distinguished Expert, leader of Guangdong" Pearl River Talent Program" Introduced Innovation and Entrepreneurship Team, and former chief scientist of the "973 Program" of the Ministry of Science and Technology.

He used to be a tenured professor in the Department of Cell Biology and Physiology, School of Medicine of University of Pittsburgh, served as a reviewer of a number of projects under U.S. NIH and U.K. Welcome Trust foundations, published research papers as the first author or correspondent in high-end journals, including Nature series (Nature Neuroscience and Nature Medicine), Neuron, PNAS, GUT, JCI, Diabetes, JBC, and has rich entrepreneurial experience in the pharmaceutical industry.

Li Fanghong MD

Co-founder & CMO

Li Fanghong, MD, co-founder of Sinogen, National Distinguished Expert, 2012 Jiangsu High-level Innovative and Entrepreneurial Talent, 2017 Guangzhou Development Zone Entrepreneur Talent, 2018 Guangzhou Development Zone Outstanding Class A Talent, the first core member of 2017 Guangdong Innovation Team, and leader of 2019 Guangzhou Innovation Team.

She has obtained the qualification certificate of American pathologist and the medical license in Maryland, USA. She focuses on the research and development of innovative drugs for chronic critical diseases, and has participated in/presided over, and completed a number of national and provincial scientific research projects. She has published more than 20 academic articles in international journals, including Nature Medicine, American Journal of Pathology, Molecular Endocrinology, and Biochem J, and applied for and was granted more than 20 patents for inventions.

Huang Jian

CFO

Mr. Huang Jian holds a Bachelor’s degree in Finance from the University of British Columbia and a Master’s degree from Tongji University. With over 21 years of experience in finance and financial management, he has held positions at renowned companies such as Intesa Sanpaolo, Agile Group, and Star River Group. He has led multiple large-scale financing and investment projects as well as the establishment of corporate financial systems. Mr. Huang is a certified ACCA and CGA member, and holds qualifications in fund and securities trading. He has led the completion of over 25 billion RMB in domestic and international financing, and participated in the investment and exit of various high-profile projects, including E-House, Agile Living, Ping An Financial Technology, and CloudWalk Technology.

Zhou Sujin PhD

R&D Director

Zhou Sujin, PhD, core member of "Pearl River Talent Program" Introduced Innovation and Entrepreneurship Team, and "Hundred Young Talents Program" Introduced Talent of Guangdong University of Technology.

Over the past 10 years, she stayed focused on the research of tumor metabolism and the mechanism and clinical transformation of oncolytic bacteria, and has accumulated rich experience in preclinical pharmacodynamic research, mechanism of actions of drugs, manufacturing process and new drug clinical registration application of oncolytic bacteria. The oncolytic bacteria SalMet-Vec®, of which she presided over and participated in the research and development, has obtained two clinical approvals from FDA. Currently, she has applied for 39 invention patents (including PCT) as the main inventor, with 15 granted (4 granted in China and 11 granted internationally). Some research results have been published in international journals.

Christie Chiu

Global Clinical Operation Director

Ms. Christie Chiu graduated from National Taiwan University, with a master's degree in epidemiology at the College of Public Health, and has over 21 years of experience in clinical trial development and more than 10 years of experience in team management and inter-departmental integration management. She has worked for domestically and internationally renowned CRO companies such as Parexel APEX, i3 Research and FMD, and has a certified CRA (CCRA) qualification awarded by the International Association of Clinical Research Professionals (ACRP). She has comprehensive experience in managing international, multinational, and multicenter key clinical trials. She, as a Global Project Manager, has led several phase III clinical trials in Asian countries, involving oncology (HCC, NSCLC, FLL, ovarian cancer, etc.) and infectious diseases (HBV＆HCV), etc.

Edwin Chen

CEO

Mr. Chen Huode (Edwin), Expert of the Expert Committee, GD·FDTAEC Association Member of the Quality Authorized Person Committee, Provincial Pharmaceutical Society Jinan University EMBA. Holder of multiple patents, author of six papers in national core journals, and recipient of the "Guangzhou Development District Outstanding Skilled Talent" award.

With nearly 20 years in the pharmaceutical industry, Mr. Chen is a leading figure in the industrialization of bacterial vector-based anti-tumor drugs. He led the formation of the core team, oversaw the construction of China's first dedicated production workshop for such drugs, and established a global quality management system meeting both FDA and China GMP standards. He also guided the team to obtain the nation's first Production License A Certificate in this field, filling a critical industry gap. Leveraging his extensive experience at major domestic and international pharma companies, he is skilled in innovative drug pipeline development, enterprise operations, and team management. With a professional, internationally compliant, and forward-looking vision, he is committed to making Huajin Pharmaceuticals a benchmark for innovative bacterial biopharmaceuticals in China and advancing Chinese original biologics onto the global stage.

Du Tao / PhD

Du Tao, PhD from McGill University in Canada, postdoctor from Harvard University in the United States, National Distinguished Expert, and the former FDA review officer.
He has over 20 years of work experience in pharmaceutical regulatory affairs. He has reviewed IND and NDA applications of more than 100 drug products at FDA, participated in drafting and writing the first edition of the FDA Botanical Drug Guidance, and received several awards from FDA. After that, he served as a senior director of the Clinical and Registration Department in UnitedHealthcare in the United States and Hutchison Whampoa in Hong Kong. Since 2005, he worked as a professional pharmaceutical development consultant and has led a number of teams from different countries to successfully complete the development and application of more than 30 new drugs. During this period, he has also assisted several domestic and foreign pharmaceutical companies in completing a number of technology transfers and corporate mergers and acquisitions. He is presently the chief consultant of HPC in the United States, and the visiting professor at North Carolina State University, Peking Union Medical College, etc.

Dai Yifan / PhD

Dai Yifan, PhD, Distinguished Professor of Nanjing Medical University, doctoral advisor, National Distinguished Expert, Yangtze River Scholar by the Ministry of Education, molecular biology expert, and leading talent of Jiangsu Scientific and Technological Innovation Team.
He has engaged in scientific research successively at Salk Institute in California, Baxter Healthcare and Revivicor Inc. in the United States, and served as the associate professor at Starzl Transplantation Institute, Department of Surgery, School of Medicine at University of Pittsburgh in the United States. Since 2009, he has served as the distinguished professor of Nanjing Medical University and the director of Jiangsu Key Laboratory of Xenotransplantation. His research results have been published in Science and Nature series journals, respectively, and were listed in the top 100 greatest scientific news in the world by the Discover journal in the United States twice in 2002 and 2006. He won the Fujisawa Award for Young Scientists in the field of organ transplantation.

Du Xin / PhD

Du Xin, PhD from University of Florida, postdoctor from National Academy of Medicine, USA, and former FDA CMC reviewer responsible for IND and BLA review of biologics. He has worked for Aventis-Pastuer/Sanofi, Wyeth/Pfizer, Novartis, BMS, and NPS, etc. Dr. Du is a drug research and development expert with over 20 years of biopharmaceutical experience and is a cross-border regulatory expert between FDA and the industry with uniquely integrated experience in drug registration and drug research and development.

Zhang Dan / PhD

National Distinguished Expert, academician of the Russian Academy of Engineering, and co-founder and chief strategy officer of ClinChoice Pharma.
He has successively obtained a degree of doctor of medicine from Peking Union Medical College, a master's degree in public health from Harvard University, and a master's degree in medical management from Wharton School of the University of Pennsylvania. He used to be the first chairman of the Greater China region of Quintiles Transnational Corp, the world's largest multinational CRO, and successfully opened up the Greater China market. He is presently the head of the ICH E19 IFPMA Expert Committee and an expert of the NMPA ICH Working Group.

Richard G. Moore / M.D.

Professor of the School of Medicine, University of Rochester, oncologist, and a fellow of the American College of Surgeons (ACS). Dr. Moore graduated from the School of Medicine of University of Alberta in Canada, and completed his residency and fellowship at Eastern Virginia Medical School and Women & Infants Hospital/Brown University. He used to be an associate director of the Women's Oncology Program of the Women & Infants Hospital/Brown University, director of the Emerging Technology and Molecular Therapeutics Laboratory, and is an internationally recognized first-class expert in the detection of ovarian cancer biomarkers. He has led a team to create an FDA-approved method for detecting ovarian cancer in patients with ovarian cysts or pelvic masses.

Zheng Li / PhD

Director of GCP Center, West China Hospital of Sichuan University, professor and postgraduate supervisor.
She has been engaged in clinical research on innovative drugs for infectious immune diseases and tumors for more than 20 years.
She, as a project leader, is responsible for more than 60 clinical researches on new drugs,and more than 20 first-in-human trials of Category 1.1 innovative drugs, including over 10 clinical researches on innovative manufacturing of national major new drugs such as Donafenib, Herombopag, SHR-1314, IL-22, TNHH, etc., and has participated in one major project under each of the 12th and 13th Five-Year Plans issued by the Ministry of Science and Technology of China, and presided over one major research platform project of Science and Technology Department of Sichuan Province.
She specializes in phase I clinical studies and overall development of phase II and III clinical trials of innovative drugs in multiple fields, including tumor-targeted biological macromolecule and small molecule drugs, immunomodulatory and immunosuppressive drugs,
and has rich research experience in design of model-based adaptive protocols, quality control of clinical project implementation and risk control of early stage clinical researches.

Qi-Chun Cai / M.D., Prof

Director and Lead Specialist, Oncology Center, Clifford Hospital

Dr. Qi-Chun Cai is an experienced oncologist and immunotherapy researcher, serving as the Director of the Oncology Center at Clifford Hospital. With a medical education spanning undergraduate to doctoral levels from Sun Yat-sen University, she has nearly 30 years of expertise in cancer treatment and research.

Dr. Cai focuses on the study of tumor immune microenvironment and first proposed the "Holistic Tumor Immunotherapy Theory" in 2005, which effectively awakens and enhances patients' anti-tumor immunity. She has published more than 40 peer-reviewed articles in renowned journals such as Nature Medicine, participated in 6 provincial-level or above funds and also in multiple international and domestic clinical drug trial studies. Her clinical and research focus includes immunotherapy for malignant lymphoma, lung cancer, gastrointestinal cancers, and other solid tumors.

Shen Hua / PhD

Director of Department of Medical Oncology, Sir Run Run Hospital of Nanjing Medical University, PhD in oncology, chief physician, associate professor, and master supervisor.
Academic positions: Young member of Precision Tumor Therapy Committee of China Anti-Cancer Association, Standing member of Gastric Tumor Marker Cooperative Group of Tumor Marker Committee of China Anti-Cancer Association, Member of Abdominal Tumor Committee of China Medical Education Association, Member of Oncology Branch of Jiangsu Geriatrics Association, Member of Popular Science Society of Jiangsu Society of Immunology, Member of Rectal Cancer Anus-Preserving Committee of Jiangsu Research Hospital Association, Distinguished Young and Middle-Aged Academic Leader of Nanjing Medical University, Talent of Jiangsu "333" Talent Project, High-Caliber Talent of Jiangsu "Six Talent Peaks Project", and Young Medical Talent of the 13th Five-Year Plan of Jiangsu Commission of Health.

Allan Zijian Zhao, PhD, founder and chairman of Sinogen, National Distinguished Expert, leader of Guangdong" Pearl River Talent Program" Introduced Innovation and Entrepreneurship Team, and former chief scientist of the "973 Program" of the Ministry of Science and Technology.
He used to be a tenured professor in the Department of Cell Biology and Physiology, School of Medicine of University of Pittsburgh, served as a reviewer of a number of projects under U.S. NIH and U.K. Welcome Trust foundations, published research papers as the first author or correspondent in high-end journals, including Nature series (Nature Neuroscience and Nature Medicine), Neuron, PNAS, GUT, JCI, Diabetes, JBC, and has rich entrepreneurial experience in the pharmaceutical industry.

Allan Zijian Zhao PhD

Chairman

Li Fanghong, MD, co-founder of Sinogen, National Distinguished Expert, 2012 Jiangsu High-level Innovative and Entrepreneurial Talent, 2017 Guangzhou Development Zone Entrepreneur Talent, 2018 Guangzhou Development Zone Outstanding Class A Talent, the first core member of 2017 Guangdong Innovation Team, and leader of 2019 Guangzhou Innovation Team.
She has obtained the qualification certificate of American pathologist and the medical license in Maryland, USA. She focuses on the research and development of innovative drugs for chronic critical diseases, and has participated in/presided over, and completed a number of national and provincial scientific research projects. She has published more than 20 academic articles in international journals, including Nature Medicine, American Journal of Pathology, Molecular Endocrinology, and Biochem J, and applied for and was granted more than 20 patents for inventions.

Li Fanghong MD

Director

Du Tao, PhD from McGill University in Canada, postdoctor from Harvard University in the United States, National Distinguished Expert, and the former FDA review officer.
He has over 20 years of work experience in pharmaceutical regulatory affairs. He has reviewed IND and NDA applications of more than 100 drug products at FDA, participated in drafting and writing the first edition of the FDA Botanical Drug Guidance, and received several awards from FDA. After that, he served as a senior director of the Clinical and Registration Department in UnitedHealthcare in the United States and Hutchison Whampoa in Hong Kong. Since 2005, he worked as a professional pharmaceutical development consultant and has led a number of teams from different countries to successfully complete the development and application of more than 30 new drugs. During this period, he has also assisted several domestic and foreign pharmaceutical companies in completing a number of technology transfers and corporate mergers and acquisitions. He is presently the chief consultant of HPC in the United States, and the visiting professor at North Carolina State University, Peking Union Medical College, etc.

Du Tao PhD

Director

Dai Yifan, PhD, Distinguished Professor of Nanjing Medical University, doctoral advisor, National Distinguished Expert, Yangtze River Scholar by the Ministry of Education, molecular biology expert, and leading talent of Jiangsu Scientific and Technological Innovation Team.
He has engaged in scientific research successively at Salk Institute in California, Baxter Healthcare and Revivicor Inc. in the United States, and served as the associate professor at Starzl Transplantation Institute, Department of Surgery, School of Medicine at University of Pittsburgh in the United States. Since 2009, he has served as the distinguished professor of Nanjing Medical University and the director of Jiangsu Key Laboratory of Xenotransplantation. His research results have been published in Science and Nature series journals, respectively, and were listed in the top 100 greatest scientific news in the world by the Discover journal in the United States twice in 2002 and 2006. He won the Fujisawa Award for Young Scientists in the field of organ transplantation.

Dai Yifan PhD

Director

Zhou Sujin, PhD, core member of "Pearl River Talent Program" Introduced Innovation and Entrepreneurship Team, and "Hundred Young Talents Program" Introduced Talent of Guangdong University of Technology.
Over the past 10 years, she stayed focused on the research of tumor metabolism and the mechanism and clinical transformation of oncolytic bacteria, and has accumulated rich experience in preclinical pharmacodynamic research, mechanism of actions of drugs, manufacturing process and new drug clinical registration application of oncolytic bacteria. The oncolytic bacteria SalMet-Vec®, of which she presided over and participated in the research and development, has obtained two clinical approvals from FDA. Currently, she has applied for 39 invention patents (including PCT) as the main inventor, with 15 granted (4 granted in China and 11 granted internationally). Some research results have been published in international journals.

Zhou Sujin PhD

Director

Co-founder of Share Capital, and managing partner of Medical & Healthcare Fund
Bachelor's degree in accounting from Jiangsu University, and MBA from China Europe International Business School (CEIBS). Prior to joining Share Capital, he has served as the chief financial officer of Philips Consumer Communications, chief financial officer of Walmart China, and managing director, deputy general manager and chief financial officer of a listed company
Mr. Huang has over 10 years of venture capital experience and has invested in over 70 enterprises, many of which have been successfully exited through IPO. He is presently a mentor for entrepreneurship training of the Thousand Talents Program, a mentor of the China Europe Smart Healthcare Startup Program, a mentor of the Peking University Health Special Training Program, and a director of the Alumni Association of China Europe International Business School (former secretary-general of the Alumni Association in Shenzhen).

Huang Fanzhi

Director

Dr. Huang Xu, executive general manager of China Capital Investment Group(CCIG), postdoctoral fellow at Harvard Medical School in the United States, national leading talent, and evaluation expert for innovative manufacturing of major new drugs under the Ministry of Science and Technology, has over 20 years of experience in startup and investment in the pharmaceutical industry.

Huang Xu PhD

Director